With sub­par sales for Leqem­bi, Ei­sai de­lays Alzheimer’s pa­tient goal dead­line

Ei­sai said it could strug­gle to meet up­take tar­gets for its Bio­gen-part­nered Alzheimer’s drug Leqem­bi by the end of March as it de­tailed dis­ap­point­ing fis­cal third quar­ter sales for the in­tra­venous ther­a­py.

Leqem­bi won US ac­cel­er­at­ed ap­proval in Jan­u­ary 2023 with full ap­proval fol­low­ing in Ju­ly. Ei­sai has high hopes for the treat­ment, pro­ject­ing it could reach $7 bil­lion in glob­al sales by 2030.

But Leqem­bi sales of al­most $7 mil­lion in the three months lead­ing up to De­cem­ber 2023 fell short of Vis­i­ble Al­pha con­sen­sus es­ti­mates of $9.3 mil­lion. The drug has been ad­min­is­tered to around 2,000 pa­tients in the US, with four times that num­ber on wait lists, Ei­sai’s glob­al Alzheimer’s of­fi­cer Keisuke Naito said on its earn­ings call Tues­day that was trans­lat­ed live from Japan­ese.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER